PharmaFocus: Visual Analysis of Immuno-Oncology Development and Opportunities

2017-08-18
Price :
Published : Aug-2017
No. of Pages : 182
Table of Contents
1. Preface
1.1 Related Reports 4
1.2 Upcoming Reports 5
1.3 Abbreviations 6
2. Immuno-Oncology Product Definition and Classification 7
3. Recent Timeline of Immuno-Oncology Approvals 11
4. Immune Checkpoint Modulators - Trends in Clinical Trial Development 19
4.1 Clinical Trial Activity for Checkpoint Modulators Remains Essentially Driven by PD-(L)1 and CTLA-4 Targeting Agents 20-25
4.2 Academic Institutions Are Key Drivers for Early Stage Clinical Research, but Patient Recruitment is Highly Dependent on Companies 26-32
4.3 Geographic Locations of Trials Assessing Immune Checkpoint Modulators 33-37
5. Competitive Assessment of Marketed PD-(L)1 Checkpoint Modulators 38
5.1 Clinical Positioning of Marketed PD-(L)1 Inhibitors 39-45
5.2 Commercial Attributes of Marketed PD-(L)1 Checkpoint Modulators 46-56
5.3 Dynamic of Clinical Development for Marketed PD-(L)1 Checkpoint Modulators 57-61
5.4 Clinical Development Coverage of Marketed PD-(L)1 Checkpoint Modulators in Solid Tumors and Blood Cancers 62-71
6. Emergence of New Immune Checkpoint Targets 72
6.1 Emergence of New Checkpoint Targets in Clinical Development 73-79
6.2 Clinical Development Coverage of Emerging Targets in Solid Tumors and Blood Cancers - Matrix Analysis 80-89
7. Cellular Immunotherapies in Clinical Development 90
7.1 Clinical Development of Cellular Immunotherapies 91-98
7.2 Clinical Development of Cytotoxic Cellular Immunotherapies 99-110
8. Clinical and Commercial Opportunities for Highly Anticipated CAR Cell Therapies 111
8.1 Development of and Opportunities for CAR Cell Therapies 112-123
8.2 Development of CAR Cell Therapies in Blood Cancers 124-130
8.3 Development of CAR Cell Therapies in Solid Tumors 131-137
9. Cell Vaccines: Steady Development Stimulated by Prior IO Success 138
9.1 Trends in Clinical Development of Cancer Vaccines 139-152
10. T-cell Redirecting Therapies: Comparison Between CAR Cell Therapies and Bispecific T-Cell Engager Antibodies 153
10.1 Development of CAR Cell Therapies and Bispecific T-Cell Engagers 154-161
11. Promising IO-IO Combinations Utilizing Oncolytic Viruses 162
11.1 Combination Strategies of Oncolytic Viruses with Other IO Agents Create New Clinical Opportunities 163-169
12. Appendix 170
12.1 Inclusion Criteria for IO Products 171
12.2 Exclusion Criteria for IO Products 172
12.3 Identification of Immuno-Oncology Products Based on Targets and Molecule Types 173
12.4 Data Export from the Pharma Intelligence Center 174
12.5 Primary Research 175-176
12.6 Bibliography 177
12.7 About the Authors 178-179
12.8 About GlobalData 180
12.9 Contact Us 181
12.10 Disclaimer 182

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare
Publisher : GlobalData